5593734063 · Bioteknisk forskning och utveckling · FLYINGE
Source: Bolagsverket and Statistics Sweden (SCB), public registers, updated continuously. A missing value does not mean the company is inactive.
In 2025, net sales rose 223.1 % to 44 MSEK. Raaven Therapeutics AB lifted its operating margin from 21.1 % to 73.2 % in 2025. With an operating margin of 73.2 %, the company ranked at the 89th percentile among 299 companies in its industry. Each of the three most recent comparable fiscal periods (2023–2025) ended in profit.
Calculated by ArkivNord from filed annual reports. About the methodology
Positive signals from the latest annual accounts. See the Analysis tab for the full calculation behind each badge.
Net revenue
44 MSEK
▲ +222%Net result
19.5 MSEK
▲ +738%Employees
6
Per the signatures in the annual report for the fiscal year ending 2025-12-31.
This shows who signed the most recent parsed annual report — not a live register. Positions may have changed since filing.
arkivnord